Daraxonrasib is the first investigational agent in a novel class of RAS (ON) multi-selective inhibitors designed to address a diverse and broad spectrum of RAS variants. In the randomized Phase 3 ...
Previous clinical trials suggested that ultra-thin strut biodegradable polymer sirolimus-eluting stent (BP-SES) may be ...
Tiger BioSciences announced the publication of interim data from the ongoing TIGERCAMP randomized controlled trial (RCT), now ...
First patient dosed marks rapid transition from trial activation to active treatment in patients with acute lung injury from ...
Morning Overview on MSN
A daraxonrasib trial just held pancreatic cancer in check for 8.5 months in most patients — twice as long as standard chemo for tumors that spread after first-line tr…
Pancreatic cancer is the third-leading cause of cancer death in the United States, and for patients whose tumors spread after ...
Phase 3b ENCORE data assess inhaled amikacin in MAC lung disease. Read more on efficacy, safety, and patient-reported ...
Morning Overview on MSN
A daily multivitamin slowed all five epigenetic aging clocks in a randomized trial — people who started biologically older benefited most
Among nearly 1,000 older adults randomly assigned to take either a daily multivitamin or a placebo for two years, those in the supplement group aged more slowly at the molecular level, according to ...
Idiopathic normal-pressure hydrocephalus is a neurologic disorder characterized by impaired gait, balance, cognition, and bladder control in older adults. The disorder is treated with shunt surgery, ...
Results presented at oncology conference in Chicago show Galleri test failed to reduce late-stage cancer diagnoses ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results